Menlo Therapeutics Inc. (MNLO)
Market Cap | 226.38M |
Revenue (ttm) | 13.44M |
Net Income (ttm) | -246.03M |
Shares Out | 138.65M |
EPS (ttm) | -5.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | Sep 4, 2020 |
Last Price | $1.35 |
Previous Close | $1.35 |
Change ($) | 0.00 |
Change (%) | 0.00% |
Day's Open | - |
Day's Range | 1.30 - 1.39 |
Day's Volume | 0 |
52-Week Range | 1.00 - 7.48 |
News
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will pres...
BRIDGEWATER, N.J., Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc.
Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call Transcript
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020.
MNLO's enterprise valuation at $1.70/share is
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead
The pricing of the biotech's stock offering weighed on shares.
Menlo Therapeutics Inc (NASDAQ: MNLO) shares are trading lower on Friday, after the company reported a common stock offering of 27.05 million shares at $1.85 per share.
BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietar...
BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietar...
Menlo Therapeutics: Dip In Share Price Post Zilxi Approval Presents A Good Buying Opportunity
BRIDGEWATER, N.J., May 29, 2020 /PRNewswire/ -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing ...
ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Should The FDA Approve Menlo Therapeutics Latest Therapy Shares Should Do Well
Menlo Therapeutics' (MNLO) CEO Dave Domzalski on Q1 2020 Results - Earnings Call Transcript
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Transaction provides non-dilutive capital including $10M up-front Transaction provides non-dilutive capital including $10M up-front
There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.
Conference call today at 8.30am EDT Conference call today at 8.30am EDT
BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceutica...
Menlo Is A Good Bet Reflecting The Upcoming Catalysts
Menlo Therapeutics Inc. shares MNLO, -11.47% slid 25% in premarket trade Wednesday, after the biopharmaceutical company said a mid-stage trial of a treatment for chronic pruritus, a form of sk...
Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO Da...
REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treat...
Steven Cohen (Trades, Portfolio), manager of Point72 Asset Management, disclosed this week that his firm established a new holding in Menlo Therapeutics Inc.
Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Earnings & Merger Announcement with Menlo Therapeutics Conference (Transcript)
Shares of Menlo Therapeutics Ltd. MNLO, -9.09% was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. FOMX, -27.53% plunged 16%, after the company's announced a me...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) (“Foamix”) and Menlo Therapeutics Inc. (Nasdaq: MNL...
Pruritogenic responses usually evolve from chronic diseases predominantly affecting the skin and liver.
- Pivotal results expected in March/April 2020 -
-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant-
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical...
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the trea...
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
- Results expected in Q1 2020 -
REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treat...
Menlo Therapeutics is clinical-stage biopharma developing innovative therapeutics for pruritus associated with skin diseases.
Menlo Therapeutics has been focused on its main pipeline and clinical product for the treatment of pruritus.
About MNLO
Menlo Therapeutics, a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of mode... [Read more...]
Industry Biotechnology | IPO Date Jan 25, 2018 |
CEO David Domzalski | Country United States |
Stock Exchange NASDAQ | Ticker Symbol MNLO |